Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.25 -0.25 (-7.14%)
As of: Oct 20, 2026 · 3:58 PM EDT

Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) recorded Other Non-Current Liabilities of $257,000 in Q2 2026, up 47.4% from $174,413 a year earlier.

Analysis

Apimeds Pharmaceuticals US (APUS) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends

At the end of FY2025, Apimeds Pharmaceuticals US reported Other Non-Current Liabilities of $1.62 million.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Apimeds Pharmaceuticals US 5.65 Mn -13.98 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 257,000.00
Dec 31, 2025 1.62 Mn
Jun 30, 2025 174,413.00
API Access

Apimeds Pharmaceuticals US Other Non-Current Liabilities API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-non-current-liabilities&ticker=APUS&period=max&api_key=YOUR_API_KEY